Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and…
Puma Biotechnology and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part…
Read More...
Read More...